Spots Global Cancer Trial Database for Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Official Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Study ID: NCT00950911
Interventions
Study Description
Brief Summary: The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (Zometa®) or denosumab.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Jindrichuv Hradec, , Czech Republic
Research Site, Kromeriz, , Czech Republic
Research Site, Olomouc, , Czech Republic
Research Site, Praha 1, , Czech Republic
Research Site, Praha 4, , Czech Republic
Research Site, Praha 4, , Czech Republic
Research Site, Praha 5, , Czech Republic
Research Site, Praha 6, , Czech Republic
Research Site, Zlin, , Czech Republic
Research Site, Chichester, , United Kingdom
Research Site, Leeds, , United Kingdom
Research Site, London, , United Kingdom
Research Site, London, , United Kingdom
Research Site, Manchester, , United Kingdom
Research Site, Northwood, , United Kingdom
Research Site, Peterborough, , United Kingdom
Research Site, York, , United Kingdom
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
